Higher carotid-radial pulse wave velocity is associated with non-melancholic depressive symptoms in men – findings from Helsinki Birth Cohort Study

Mia D. Eriksson, Johan G. Eriksson, Hannu Kautiainen, Minna K. Salonen, Tuija M. Mikkola, Eero Kajanto, Niko Wasenius, Mikaela von Bonsdorff, Päivi Korhonen, and Merja K. Laine

ABSTRACT

Background: Depression and cardiovascular disease (CVD) are major causes of global disease burden that are interrelated through mostly unknown mechanisms. We studied the relationship of melancholic and non-melancholic depressive symptoms with arterial stiffness, an important underlying mechanism of CVD.

Methods: The Helsinki Birth Cohort Study recruited 683 previously extensively phenotyped subjects for this sub-study. Cross-sectional data along with responses regarding depressive symptoms were obtained for each participant. For evaluation of depressive symptoms, the Beck Depression Inventory (BDI) and subscales were used to measure melancholic and non-melancholic depressive symptoms. Arterial stiffness was assessed as pulse wave velocity (PWV) that was measured between the carotid and radial artery, and carotid and femoral artery.

Results: Of the participants, 532 scored <10 on the BDI and were classified as not having depressive symptoms. Of the 151 participants that scored ≥10 on the BDI, 122 were classified as having non-melancholic depressive symptoms and 29 as having melancholic depressive symptoms. Men had higher carotid-radial PWV (crPWV) values than women (p < .001). A positive relationship between BDI scores and crPWV (p < .001) was found in men. We also found higher crPWV in men with non-melancholic depressive symptoms compared to all others. No such differences were found in women.

Discussion: Arterial stiffness has a relationship with depressive symptoms and subtypes of depressive symptoms, at least in men. There is a significant relationship between higher PWV and non-melancholic depressive symptoms in men. Due to the intricate nature of the disease causality or directionality is impossible to infer solely based on this study. Further studies into the subtypes of depressive symptoms may be of benefit to understanding depression.

KEY MESSAGES

- It is known that arterial stiffness contributes to cardiovascular disease, and is associated with depression.
- Higher Beck Depression Inventory scores are associated with higher carotid-radial pulse wave velocity in men.
- Non-melancholic depressive symptoms are associated with higher carotid-radial pulse wave velocity in men.
Over 322 million individuals worldwide are affected by depression, which is the leading cause of years lost to disability in the world [1] and an enormous contributor to the overall burden of disease [2]. The World Health Organization has predicted that by 2030 it will globally be the leading cause of burden of disease [3]. Depression has been shown to have been associated with a two-fold increased risk of death that cannot entirely be explained by behaviour or physical illness [4].

Depression is also strongly intertwined with physical health, including cardiovascular disease (CVD) [2]. Independent associations with depression for oxidative stress, increased inflammation, endothelial dysfunction, and arterial stiffening have been reported [5,6]. These same factors are also associated with CVD [5–7]. Recent research has shown an association between depressive symptoms and CVD even at depressive levels lower than indicative of depressive disorder [8]. This implies that there may be no lower limit of when depression begins to be associated with CVD [8]. It was also shown that this relationship between depressive symptoms and CVD is not dependent on cardiovascular risk factors [8].

The vascular hypothesis of depression is based on the concept that vascular disease can alter brain function by affecting perfusion and disrupting regional brain connectivity, which in turn can lead to clinical symptoms [9]. Arterial stiffness and increased flow pulsatility cause harm to the cerebral microvasculature [10–12]. Arterial pulsatility propagates directly from central vessels into cerebral vessels causing angiopathy [13]. Microvascular damages, especially in the frontal-subcortical mood regulatory regions, are believed to be one underlying cause of depression [11,14–20].

Arterial stiffness contributes greatly to the progression of CVD and reflects structural vessel wall changes leading to faster arterial wave propagation within the blood vessels [13]. Pulse wave velocity (PWV) is a method of assessing arterial stiffness in both clinical and subclinical vascular disease [21–26]. The measurement calculates the speed of the pulse wave in the aorta or peripheral arteries [23]. Prior studies have shown an association between depression or depressive symptoms and aortic stiffness in adults [5,27,28]. No such association has, however, been reported in older adults [27,29], nor in relation to melancholic or non-melancholic types of depression.

Prior research has indicated that melancholic and non-melancholic depression are associated with different underlying mechanisms [30,31]. Non-melancholic depression has been connected to metabolic and inflammatory dysregulations, whereas melancholic depression seems to be associated with an underlying hypothalamic-pituitary-adrenal (HPA)-axis dysregulation [30,31]. Dyslipidemia, high blood pressure and CVD are markers of metabolic dysregulation [30,31], leading us to hypothesize that non-melancholic depressive symptoms would have a stronger relationship with arterial stiffness than melancholic depressive symptoms.

The aim of this study was to assess arterial stiffness measured as PWV, and its relationship to depressive symptoms. We specifically focused on PWV differences between melancholic and non-melancholic depressive types. To the best of our knowledge, no studies have yet looked at PWV in relation to melancholic and non-melancholic depressive symptoms. Due to differing levels of cardiovascular risk factors and prevalence of depression between sexes we have also looked at any findings separately for men and women.

**Materials and methods**

**Participants**

The Helsinki Birth Cohort Study (HBCS) is composed of 13,345 men and women born between 1934 and 1944 at either Helsinki University Hospital or Helsinki City Maternity Hospital in Helsinki, Finland. Each subject attended child welfare clinics in Helsinki. The majority of subjects also attended school in Helsinki. Prior publications have detailed the records attained regarding birth, child welfare, and school health records [32,33].

By 1971 the members of the Finnish population were each given a unique identification number. From the original cohort, 8760 individuals (4630 men and 4130 women), all born at Helsinki University Hospital, were identified. In 2001–2004, 2902 subjects were identified for participation in further studies. These subjects were selected using random-number tables from those who were still alive and living in Finland. Out of the subjects identified 2003 individuals took part in the study. From this group of 2003, 1404 individuals were identified in 2011 as still being alive and living within 100 km of the study clinic in Helsinki. Of these subjects, 1094 participated in further clinical studies. In 2017–2018 these same criteria were used to identify subjects, of which 815 individuals participated in the study at hand. Of these, in 132 subjects PWV measurements were not obtained due to physical limitations of...
The participants or technical issues. These subjects were hence excluded from the study, and therefore 683 subjects had data available on the variables and were ultimately included in the current study.

**Ethics**

The protocol (Dnro HUS/2020/2016) of the study was approved by the Coordinating Ethical Committee of the Hospital District of Helsinki and Uusimaa. Each subject gave written informed consent prior to participation. All study procedures followed the ethical guidelines set by the declaration of Helsinki.

**Depressive symptoms**

The Beck Depression Inventory (BDI) was used to assess depressive symptoms among the subjects. The BDI is a 21-category self-reported questionnaire of behavioural manifestations of attitudes and symptoms specific to depression [34]. The range for the BDI is 0–63 points [35]. A cut-off of ≥10 total points was utilized to identify increased depressive symptoms. The BDI has been validated to screen for mild to severe clinical depression using the ≥10 point cut-off [35].

The subjects were classified as having either melancholic or non-melancholic depressive symptoms according to the presence or absence of melancholic symptoms (sadness, past failure, loss of pleasure, guilty feelings, punishment feelings, loss of interest, irritability, changes in sleep and appetite) as defined by the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) in a similar way as in prior publications [36–38]. The grouping into melancholic and non-melancholic depressive symptoms was determined by which summary score for symptoms outnumbered the other one, as described previously [36–38].

**Pulse wave velocity**

PWV was measured using a Complior mechanotransducer sensor (ALAM Medical, France). All measurements were obtained in the same room by the same trained research nurse. Each subject rested for a minimum of 10 min before measurements were obtained. The subjects were supine and at rest, during which, two separate measurements of carotid-femoral pulse wave velocity (cfPWV) and carotid-radial pulse wave velocity (crPWV) were taken each. PWV was calculated as the distance between sites divided by the time between the upstroke of pressure waves. This was adjusted by a 0.8 scaling factor as recommended not to overestimate the true distance, and hence also PWV [39,40]. The PWV ratio was calculated as cfPWV divided by crPWV in a similar manner as in prior studies [41].

**Other measurements**

Blood samples from each subject were drawn for laboratory assessment after an overnight fast. Measurements of glycated haemoglobin (HbA1c), high-sensitivity C-reactive protein (hs-CRP), and lipids were performed. A hexokinase method was utilized for the measurement of plasma glucose concentrations. Standard enzymatic methods were used to measure serum total cholesterol and triglyceride concentrations [42,43]. A Kawi stadiometer and a Seca Alpha 770 scale were used to measure height and weight, respectively. Body mass index (BMI) was calculated as the subject’s weight in kilograms divided by their height in metres squared (kg/m²).

Blood pressure was measured with the subject in a seated position. The recorded value was the mean of two successive readings from the right arm using a standard sphygmomanometer. Mean arterial pressure (MAP) was calculated as 1/3 (Systolic blood pressure) + 2/3 (Diastolic blood pressure).

A validated Kuopio Ischaemic Heart Disease Risk Factor Study 12-month leisure-time physical activity (LTPA) history questionnaire was utilized for assessment of LTPA [44]. Subjects were asked about their physical activity during the previous 12 months with regard to frequency (occasions per month), average duration, and intensity. A metabolic equivalent of task (MET)-value was assigned to each type of activity based on available databases (1 MET = 3.5 ml O₂/kg/min) [45]. The total LTPA in MET-hours (METH) is the MET values multiplied by the average duration and frequency of activity per week.

Questionnaires were utilized to gather information regarding alcohol consumption, smoking habits, health status, medication use, and socioeconomic variables (years of education, satisfaction with the financial situation, and cohabitation). Diseases diagnosed by a physician were inquired about, and the information was used to calculate the Charlson Comorbidity Index (CCI) [46]. Due to all subjects in the current study being within a narrow age range, age was not accounted for as a factor of CCI because our interest was in comorbidities without the effect of age.
Statistical analysis

The characteristics are presented as means with standard deviations (SD) for continuous variables, and as frequencies with percentages for categorical variables. The depressive symptom groups were compared with the t-test for continuous variables, and Pearson’s chi-square test or Fisher’s exact test for categorical variables. A possible nonlinear relationship between BDI and the PWV was assessed by using 4-knot-restricted cubic spline regression. The length of the distribution of knots was located at the 5th, 35th, 65th, and 95th percentiles. For restricted cubic splines, also known as natural splines, knot locations are based on Harrell’s recommended percentiles [47].

The relationship between the type of depressive symptoms and sex in regard to PWV values was evaluated using a two-way analysis of covariance with age, CCI, MAP, smoking status, and years of education as covariates. In the case of violation of the assumptions (e.g. non-normality) for continuous variables, a bootstrap-type method was used. The normality of variables was evaluated graphically and by using the Shapiro–Wilk W test. The Stata 16.1, StataCorp LP (College Station, TX, USA) statistical package was used for the analysis.

Results

Table 1 shows baseline characteristics of the 683 study subjects according to BDI score. Of the participants, 532 (78%) scored below 10 on the BDI indicating no depressive symptoms. Of the 151 (22%) participants scoring ≥10 on the BDI, indicating increased depressive symptoms, 105 (70%) were women, 122 (72%) were classified as having non-melancholic depressive symptoms, and 29 (59%) were classified as having melancholic depressive symptoms.
depressive symptoms were also less likely to be cohabitating ($p = .045$), and less likely to be satisfied with their financial situation ($p < .001$) compared to their non-depressed counterparts. They also had higher triglyceride concentrations ($p = .018$), and CCI-scores ($p = .027$). There were no differences between the melancholic and non-melancholic groups in regard to these factors. As expected, those with depressive symptoms were more likely to use anti-depressant medications ($p < .001$). There was no significant difference in use of other medications between the groups. There was no significant difference in blood pressure, the prevalence of diabetes, blood glucose concentration, high-sensitivity C-reactive protein (hsCRP), BMI, or smoking status.

Mean cfPWV was 12.75 m/s (SD 4.25) in women, and 12.87 m/s (SD 4.53) in men ($p = .71$). The corresponding values for crPWV were 10.01 m/s (1.59) and 10.69 m/s (2.98), respectively ($p < .001$).

Figure 1 shows the relationship between BDI scores and PWV according to sex. The values are adjusted for age, CCI, MAP, smoking status, and years of education. Among women, there was no relationship between BDI and cfPWV ($p = .47$) or crPWV ($p = .50$). This also applied to men and cfPWV ($p = .30$) in relation to BDI scores. There was, however, a significant relationship ($p < .001$) between BDI scores and crPWV in men.

Figure 2 shows the relationship between PWV and types of depressive symptoms separately for the sexes. This data was adjusted for age, CCI, MAP, smoking status, and years of education. For crPWV there was a significant difference ($p < .001$) between the subjects with melancholic and non-melancholic depressive symptoms, but no such difference was found with regard to cfPWV ($p = .82$). A difference between sexes was observed for crPWV ($p = .020$), but not for cfPWV ($p = .58$). No interaction was found between sex and type of depressive symptoms in relation to cfPWV ($p = .76$). For crPWV there was an interaction ($p = .009$) between sex and depressive types, with men in the non-melancholic depressive group showing the highest crPWV values. The ratio section in Figure 2 shows that there is a difference in PWV ratios between men and women ($p = .009$), but no difference between the types of depressive symptoms, and no interaction between depressive symptoms and sex in regard to the PWV ratio.

**Discussion**

In accordance with previous studies, those participants who exhibited depressive symptoms were older, more likely women, and had a higher alcohol consumption. As we hypothesized, the results of this study support a stronger connection between vascular disease and non-melancholic depressive symptoms than melancholic ones. We believe this is due to the underlying causes of the depressive subtypes. As indicated in the introduction arterial stiffening falls under metabolic dysregulation, which is more closely associated with non-melancholic than melancholic depression [30,31]. We also found a difference between the sexes, and an interaction between sex and depressive categories.
Figure 2. Pulse wave velocity (carotid-femoral and carotid-radial) in men and women based on type of depressive symptoms (measured by Beck Depression Inventory [BDI]): no depressive symptoms, non-melancholic depressive symptoms, or melancholic depressive symptoms. Adjusted for age, CCI, MAP, smoking status, and years of education. Ratio figure represents carotid-femoral pulse wave velocity divided by carotid-radial pulse wave velocity. DS: depressive symptoms; <10: <10 points on BDI, no depressive symptoms; MeD: melancholic depressive symptoms; NmeD: non-melancholic depressive symptoms.
differences in the ratios between sexes is unlikely explained by age.

There is a known difference between men and women in PWV [27] and cardiovascular risk [55,56] in relation to depressive symptoms. This brings up the question of what causes these increases in PWV to only be noticeable in male subjects. Due to the age of the subjects at hand, any differences between the men and women are unlikely to have been caused by any hormonal differences between the sexes. Studies, such as the Maastricht study [27] and the Framingham study [52], have reported differences in PWV between men and women in younger age groups as well. This may indicate that any such differences may stem as far back as intrauterine effects on the cardiovascular system [57].

Recent studies have shown that the brain-gut-vascular axis may be a possible inflammatory connection between depression and arterial stiffness [58]. Psychoneuroimmune modulation may trigger arterial stiffness in patients with chronic inflammatory conditions [58,59], which could lead to the reasoning that depression may also cause similar inflammatory consequences. A few studies have been able to show that chronic inflammatory conditions are associated with higher crPWV [60–63]. In some cases, the combination of inflammation and aging seemed to be the culprit [62]. One study reported high crPWV in young women [60], and another study found a positive correlation between crPWV and the duration of inflammatory disease [63]. The takeaway may be that crPWV and cfPWV react differently in response to aging and inflammation, or the combination of the two. These findings may at least partly explain our results implying that stiffening of the peripheral, but not the central artery, is associated with increased depressive symptoms in men. It has been suggested that elevated smaller-artery PWV is a marker for early vascular disease having its origin in endothelial dysfunction whereas aortic stiffening is a marker for more advanced disease [64]. This may explain the observed sex difference since CVD develops later in women than in men.

It is also a possibility that the lower LTPA in participants with depressive symptoms, compared to their counterparts without depressive symptoms, higher triglycerides, and higher CCI-scores may play some part in arterial stiffening. When comparing the non-melancholic and melancholic groups in regard to these factors we observed no difference, but it is possible that there may be some differences that we are unable to see due to the small number of participants in the melancholic group. For better evaluation of this, a larger sample would be of benefit.

The strengths of the current study are the overall sample size and extensively phenotyped participants. The homogenous age range of the subjects helps control for effects of aging within the sample, which is of benefit in the study at hand. On the other hand, this may be seen as a limitation from the point of view of the generalizability of any findings from the current study. It is also likely that due to the nature of the sample we may have a survival bias where our sample may be healthier than the average person of the same age. We had to exclude some participants due to their inability to have their PWV measured, which suggests some of the less healthy participants were left out. Others with poor health may have already passed away or declined to participate due to their health status leaving this sample on average healthier. Other limitations of this study are the rather small size of each subgroup, a community-type sample of all-European-descent-subjects, and the cross-sectional nature of the study. The results here may hence not be generalizable to different populations. Due to the nature of the cross-sectional study, we cannot infer any directionality or causality, which limits interpretations of any results to simply observing relationships.

Further studies with larger subgroups and with subjects of different ages would be required to attain more information on these factors. Such studies would allow investigation of more detailed differences within each subgroup, potentially indicating factors not seen in the current study. A further comparison of relationships between PWV and depressive symptoms among subjects with and without prior CVD or vascular stenosis may advance our understanding of the pathophysiology of depressive symptoms. For example, simultaneous intra-arterial measurements and non-invasive PWV measurements could potentially be of interest in mapping out differences in results from cfPWV and crPWV. It would also be of great interest to study further the underlying mechanism of why our current findings are only significant for men.

The fact that depression is a heterogeneous disease whose subtypes are currently distinguished based on self-reported criteria instead of testable biomarkers can be problematic [65]. Melancholic and non-melancholic depression differ in both clinical presentation and pathophysiology [30,31] but continue to be viewed as one disease. Depression is treatable, but it is also increasing in prevalence, and up to half of the depressed individuals may not be receiving adequate treatment [65]. This offers the opportunity and needs
for a better understanding of this complex disease and its subtypes. A better understanding of the pathophysiology of the depressive subtypes may enable us to eventually develop more precise and efficient treatments for depression. By analyzing differences between the depressive subtypes and their relationships to physiological mechanisms, such as PWV, we may gain more insight into why these subtypes behave so differently. The novel aspect of the current study is that, as far as we are aware, no other study has yet published results regarding PWV specifically analyzed by subtypes of depressive symptoms, and sex.

Due to the complex nature of depressive symptoms and their underlying causes, much research still lies ahead before we can conclusively determine a causal relationship. Based on the findings of this study it is likely that arterial stiffness is one of many factors affecting depression and depressive symptoms but that the overall pathophysiology is multifaceted and much more complicated. Even though there is a significant relationship between higher PWV and non-melancholic depressive symptoms in men, causality or directionality is impossible to infer solely based on this study.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
The HBCS has been supported by grants from Finska Läkaresällskapet, the Finnish Special Governmental Subsidy for Health Sciences, Academy of Finland [126775, 127437, 129255, 129306, 129907, 130326, 209072, 210595, 213225, 263924, 275074 and 315690], Samfundet Folkhälsan, Liv och Hälsa, EU FP7 [Developmental Origins of Healthy Aging (DORIAN)] project number 278603, and EU H2020-LIFECYCLE (all for the Helsinki Birth Cohort Study), European Commission, Horizon 2020 award [733206]. LIFECYCLE (all for the Helsinki Birth Cohort PHC-2014-Dyna Health grant [633595] and EU Horizon 2020-Aging (DORIAN) project number 278603, and EU H2020-

ORCID
Mia D. Eriksson http://orcid.org/0000-0001-8968-8304
Johan G. Eriksson http://orcid.org/0000-0002-2516-2060
Hannu Kautiainen http://orcid.org/0000-0003-0786-0858
Tuula M. Mikkola http://orcid.org/0000-0003-0885-2788
Eero Kajantie http://orcid.org/0000-0001-7081-8391

Mikaela von Bonsdorff http://orcid.org/0000-0001-8530-5230
Päivi Korhonen http://orcid.org/0000-0002-0244-4890
Merja K. Laine http://orcid.org/0000-0002-1848-1514

Data availability statement
The data is available from the corresponding author upon reasonable request.

References
[1] WHO. Depression and other common mental disorders [Internet]. Geneva (Switzerland): World Health Organization. 2017 [cited 2020 August 16]. https://www.who.int/news-room/fact-sheets/detail/depression
[2] WHO. Depression [Internet]. Geneva (Switzerland): World Health Organization. 2020 [cited 2020 July 25]. https://www.who.int/news-room/fact-sheets/detail/depression
[3] Malhi GS, Mann JJ. Depression. Lancet. 2018; 392(10161):2299–2312.
[4] Markkula N, Susvisaari J. Prevalence, risk factors and prognosis of depressive disorders. Duodenum. 2017; 133(3):275–282.
[5] Tiemeier H, Breteler MM, van Popele NM, et al. Late-life depression is associated with arterial stiffness: a population-based study. J Am Geriatr Soc. 2003;51(8):1105–1110.
[6] van Sloten TT, Schram MT, Adriaanse MC, et al. Endothelial dysfunction is associated with a greater depressive symptom score in a general elderly population: the Hoorn Study. Psychol Med. 2014;44(7):1403–1416.
[7] Heitzer T, Schlimzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104(22):2673–2678.
[8] Harshfield EG, Pennells L, Schwartz JE, et al. Association between depressive symptoms and incident cardiovascular diseases. JAMA. 2020;324(23):2396–2405.
[9] Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013; 18(9):963–974.
[10] Mitchell GF. Arterial stiffness and hypertension. Hypertension. 2014;64(1):13–18.
[11] Mitchell GF, van Buchem MA, Sigurdsson S, et al. Arterial stiffness, pressure and flow pulsatility and brain structure and function: the age, gene/environment susceptibility–Reykjavik Study. Brain: J Neurol. 2011;134(11):3398–3407.
[12] Thomas O, Cain J, Nasralla M, et al. Aortic pulsatility propagates intracranially and correlates with dilated
perivascular spaces and small vessel compliance. J Stroke Cerebrovasc Dis. 2019;28(5):1252–1260.

Alexopoulos GS, Meyers BS, Young RC, et al. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry. 1997;54(10):915–922.

[15] Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron. 2004;44(1):195–208.

Henskens LH, Kroon AA, van Oostenbrugge RJ, et al. Increased aortic pulse wave velocity is associated with silent cerebral small-vessel disease in hypertensive patients. Hypertension. 2008;52(6):1120–1126.

[17] Kearney-Schwart A, Rossignol P, Bracard S, et al. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke. 2009;40(4):1229–1236.

[18] Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry. 1997;154(4):497–501.

[19] Ohmine T, Miwa Y, Yao H, et al. Association between arterial stiffness and cerebral white matter lesions in community-dwelling elderly subjects. Hypertens Res. 2008;31(1):75–81.

[20] Pugh KG, Lipsitz LA. The microvascular frontal-subcortical syndrome of aging. Neurobiol Aging. 2002;23(3):421–431.

[21] Elias MF, Robbins MA, Budge MM, et al. Arterial pulse wave velocity and cognition with advancing age. Hypertension. 2009;53(4):668–673.

[22] Fewlass DC, Noboa K, Pi-Sunyer FX, et al. Obesity-related leptin regulates Alzheimer’s Aβ. FASEB J. 2004;18(15):1870–1878.

[23] Jannasz I, Sondej T, Targowski T, et al. Pulse wave velocity - a useful tool in assessing the stiffness of the arteries. Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego. 2019;46(276):257–262.

[24] Johnson TE. Recent results: biomarkers of aging. Exp Gerontol. 2006;41(12):1243–1246.

[25] Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–1187.

[26] Marioni RE, Strachan MW, Reynolds RM, et al. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes. 2010;59(3):710–713.

[27] Onete V, Henry RM, Sep S, et al. Arterial stiffness is associated with depression in middle-aged men - the Maastricht Study. J Psychiatry Neurosci. 2018;43(2):111–119.

[28] van Sloten TT, Mitchell GF, Sigurdsson S, et al. Associations between arterial stiffness, depressive symptoms and cerebral small vessel disease: cross-sectional findings from the AGES-Reykjavik Study. J Psychiatry Neurosci. 2016;41(3):162–168.

[29] Lewis TT, Sutton-Tyrrell K, Penninx BW, et al. Race, psychosocial factors, and aortic pulse wave velocity: the Health, Aging, and Body Composition Study. J Gerontol A Biol Sci Med Sci. 2010;65(10):1079–1085.

[30] Lamers F, Vogelzangs N, Merikangas KR, et al. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry. 2013;18(6):692–699.

[31] Penninx BW, Milaneschi Y, Lamers F, et al. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med. 2013;11:129.

[32] Barker DJ, Osmond C, Forsén TJ, et al. Trajectories of growth among children who have coronary events as adults. N Engl J Med. 2005;353(17):1802–1809.

[33] Eriksson JG. Developmental origins of health and disease - from a small body size at birth to epigenetics. Ann Med. 2016;48(6):456–467.

[34] Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571.

[35] Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychoogyl Rev. 1988;8(1):77–100.

[36] Seppälä J, Koponen H, Kautiainen H, et al. Association between folate intake and melancholic depressive symptoms. A Finnish population-based study. J Affect Disord. 2012;138(3):473–478.

[37] Seppälä J, Vanhala M, Kautiainen H, et al. Prevalence of metabolic syndrome in subjects with melancholic and non-melancholic depressive symptoms. A Finnish population-based study. J Affect Disord. 2012;136(3):543–549.

[38] Vanhala M, Jokelairen J, Keinänen-Kiukaanniemi S, et al. Depressive symptoms predispose females to metabolic syndrome: a 7-year follow-up study. Acta Psychiatr Scand. 2009;119(2):137–142.

[39] Huybrechts SA, Devos DG, Vermeersch SJ, et al. Carotid to femoral pulse wave velocity: a comparison of real travelled arterial path lengths determined by MRI and superficial measurements. J Hypertens. 2011; 29(8):1577–1582.

[40] van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445–448.

[41] Fortier C, Sidiibé A, Desjardins MP, et al. Pulse wave velocity ratio: a blood pressure-independent index of vascular aging. Hypertension. 2017;69(1):96–101.

[42] Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28(10):2077–2080.

[43] Lie RF, Schmitz JM, Pierre KJ, et al. Cholesterol oxidase-based determination, by continuous-flow analysis, of total and free cholesterol in serum. Clin Chem. 1976;22(10):1627–1630.

[44] Lakka TA, Salonen JT. Intra-person variability of various physical activity assessments in the Kuopio Ischaemic Heart Disease Risk Factor Study. Int J Epidemiol. 1992;21(3):467–472.

[45] Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 Compendium of Physical Activities: a second update
of codes and MET values. Med Sci Sports Exerc. 2011;43(8):1575–1581.

[46] Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.

[47] Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York (NY): Springer; 2001.

[48] Hickson SS, Nichols WW, Yasmin McDonnell BJ, et al. Influence of the central-to-peripheral arterial stiffness gradient on the timing and amplitude of wave reflections. Hypertension Res. 2016;39(10):723–729.

[49] Giannattasio C, Failla M, Lucchina S, et al. Arterial stiffening influence of sympathetic nerve activity: evidence from hand transplantation in humans. Hypertension. 2005;45(4):608–611.

[50] Giannattasio C, Failla M, Stella ML, et al. Angiotensin-converting enzyme inhibition and radial artery compliance in patients with congestive heart failure. Hypertension. 1995;26(3):491–496.

[51] Duprez DA, Kaiser DR, Whitwam W, et al. Determinants of radial artery pulse wave analysis in asymptomatic individuals. Am J Hypertens. 2004;17(8):647–653.

[52] Mitchell GF, Benjamin EJ, Kupka MJ, et al. Differential changes in central and peripheral conduit vessel stiffness with advancing age in a community-based cohort: the NHLBI Framingham Heart Study. J Am Coll Cardiol. 2002;39(A):139.

[53] Salaycik KJ, Kelly-Hayes M, Beiser A, et al. Depressive symptoms and risk of stroke: the Framingham Study. Stroke. 2007;38(1):16–21.

[54] Covic A, Siriopol D. Pulse wave velocity ratio: the new “gold standard” for measuring arterial stiffness. Hypertension. 2015;65(2):289–290.

[55] Franklin SS, Gustin W, 4th, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96(1):308–315.

[56] Segers P, Rietzschel ER, De Buyzere ML, et al. Noninvasive (input) impedance, pulse wave velocity, and wave reflection in healthy middle-aged men and women. Hypertension. 2007;49(6):1248–1255.

[57] Eriksson JG, Kajantie E, Osmond C, et al. Boys live dangerously in the womb. Am J Hum Biol. 2010;22(3):330–335.

[58] Zanoli L, Tuttolomondo A, Inserra G, et al. Anxiety, depression, chronic inflammation and aortic stiffness in Crohn’s disease: the brain-gut-vascular axis. J Hypertens. 2020;38(10):2008–2017.

[59] Zanoli L, Briet M, Empana JP, et al. Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society. J Hypertens. 2020;38(9):1682–1698.

[60] Cypiene A, Kovaitė M, Venalis A, et al. Arterial wall dysfunction in systemic lupus erythematosus. Lupus. 2009;18(6):522–529.

[61] Cypiene A, Laukevičius A, Venalis A, et al. The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin Rheumatol. 2008;27(12):1517–1522.

[62] Zanoli L, Lenti P, Boutouyrie P, et al. Pulse wave velocity differs between ulcerative colitis and chronic kidney disease. Eur J Intern Med. 2018;47:36–42.

[63] Zanoli L, Cannavò M, Rastelli S, et al. Arterial stiffness is increased in patients with inflammatory bowel disease. J Hypertens. 2012;30(9):1775–1781.

[64] Cohn JN. Arterial stiffness, vascular disease, and risk of cardiovascular events. Circulation. 2006;113(5):601–603.

[65] Akil H, Gordon J, Hen R, et al. Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018;84:272–288.